SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

SIGHINOLFI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.271
AS - Asia 1.852
EU - Europa 1.244
SA - Sud America 278
AF - Africa 56
Continente sconosciuto - Info sul continente non disponibili 4
Totale 6.705
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.176
SG - Singapore 717
PL - Polonia 576
CN - Cina 385
VN - Vietnam 245
BR - Brasile 210
HK - Hong Kong 156
IT - Italia 153
DE - Germania 109
FI - Finlandia 89
GB - Regno Unito 83
ID - Indonesia 77
JP - Giappone 70
BD - Bangladesh 67
FR - Francia 56
RU - Federazione Russa 47
CA - Canada 46
IN - India 42
SE - Svezia 37
MX - Messico 35
AR - Argentina 25
ZA - Sudafrica 19
AT - Austria 18
NL - Olanda 18
ES - Italia 17
UA - Ucraina 16
IQ - Iraq 13
TR - Turchia 13
KE - Kenya 12
CO - Colombia 10
PH - Filippine 10
TH - Thailandia 9
VE - Venezuela 9
MA - Marocco 8
EC - Ecuador 7
PE - Perù 7
PK - Pakistan 7
SA - Arabia Saudita 7
AE - Emirati Arabi Uniti 6
IE - Irlanda 6
EG - Egitto 5
CL - Cile 4
JM - Giamaica 4
LT - Lituania 4
MY - Malesia 4
PS - Palestinian Territory 4
BE - Belgio 3
CH - Svizzera 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
EU - Europa 3
IL - Israele 3
NP - Nepal 3
PY - Paraguay 3
TN - Tunisia 3
BH - Bahrain 2
ET - Etiopia 2
GR - Grecia 2
JO - Giordania 2
LB - Libano 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
UZ - Uzbekistan 2
AL - Albania 1
AM - Armenia 1
AP - ???statistics.table.value.countryCode.AP??? 1
AZ - Azerbaigian 1
BB - Barbados 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
GD - Grenada 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
LY - Libia 1
MD - Moldavia 1
MR - Mauritania 1
NO - Norvegia 1
OM - Oman 1
RO - Romania 1
RW - Ruanda 1
TG - Togo 1
TW - Taiwan 1
Totale 6.705
Salva come PNG Salva come JPEG
Città #
Warsaw 574
Ashburn 536
Singapore 406
Fairfield 331
San Jose 282
Santa Clara 212
Beijing 208
Hong Kong 153
Woodbridge 145
Seattle 134
Houston 120
Wilmington 113
Cambridge 101
Chandler 87
Dallas 70
Jakarta 70
Tokyo 70
Ho Chi Minh City 67
Council Bluffs 65
Los Angeles 64
Helsinki 63
New York 56
Hanoi 54
Dong Ket 52
Lauterbourg 49
Princeton 46
Ann Arbor 36
San Diego 36
Munich 31
São Paulo 25
London 24
Turku 24
Ferrara 23
Nuremberg 22
Washington 22
Bremen 20
Montreal 20
Mexico City 19
Orem 19
Chicago 18
Shanghai 17
Buffalo 16
Milan 16
Bologna 14
Santa Maria Di Sala 14
Frankfurt am Main 13
Brooklyn 12
Stockholm 12
Boston 11
Da Nang 11
Johannesburg 11
Portsmouth 11
San Francisco 10
Vienna 10
Atlanta 9
Chennai 9
Falls Church 9
Nairobi 9
Redwood City 9
The Dalles 9
Toronto 9
Dhaka 8
Denver 7
Haiphong 7
Moscow 7
Padova 7
Shenzhen 7
Belo Horizonte 6
Cape Town 6
Mumbai 6
Rome 6
Umeå 6
Utrecht 6
Boardman 5
Brasília 5
Can Tho 5
Charlotte 5
Des Moines 5
Guangzhou 5
Jacksonville 5
Philadelphia 5
Phoenix 5
Poplar 5
Porto Alegre 5
Rio de Janeiro 5
Tianjin 5
Verona 5
Addison 4
Athens 4
Augusta 4
Birmingham 4
Blumenau 4
Calgary 4
Chiswick 4
Dublin 4
Manchester 4
Medellín 4
Miami 4
Rabat 4
Salt Lake City 4
Totale 4.909
Salva come PNG Salva come JPEG
Nome #
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 254
Adipokines levels in HIV infected patients: lipocalin-2 and fatty acid binding protein-4 as possible markers of HIV and antiretroviral therapy-related adipose tissue inflammation 248
A Comparison Between Different Anti-Retroviral Therapy Regimes on Soluble Inflammation Markers: a Pilot Study 207
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 205
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 203
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 197
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: data from the Icona cohort 194
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 194
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 176
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 170
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 167
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 166
Disease progression in HIV Late Presenters: The role of HIV clinical indicator diseases prior to HIV diagnosis 163
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 162
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 161
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 161
HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients 158
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 156
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 145
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort * 144
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 141
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 134
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 134
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 133
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 133
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 133
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 132
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 132
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing 131
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 130
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 127
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 123
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 120
ANTIRETROVIRAL THERAPY RESTORES NAÏVE T CELL FREQUENCIES OC 8 AND FUNCTIONALITY IN PLWH 119
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 118
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 118
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 116
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study 115
COVID-19 in eastern Emilia: an unusual epidemiology in Northern Italy 115
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 113
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 109
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients 108
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort 102
Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected individuals with viral load <= 50 copies/ml: does eGFR matter? 93
IMMUNOSENESCENCE FEATURES ARE PARTIALLY RESTORED BY ANTIRETROVIRAL THERAPY 89
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 89
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 85
null 46
Totale 6.869
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.461
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.461
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202197 0 0 0 0 0 0 0 0 0 0 0 97
2021/2022339 41 18 2 5 15 44 21 27 16 39 12 99
2022/2023252 47 10 9 11 44 25 10 36 34 2 16 8
2023/2024334 14 27 29 14 46 91 11 7 5 3 2 85
2024/20251.130 25 11 115 25 138 140 32 36 175 157 148 128
2025/20262.952 290 106 246 258 419 185 423 134 287 318 238 48
Totale 6.869